RAAS inhibition and beyond—cardiovascular medications in patients at risk of or affected by COVID-19

The COVID-19 pandemic led to an enormous burden on healthcare systems worldwide. Causal therapy is still in its infancy. Contrary to initial views that the use of angiotensin-converting enzyme inhibitors (ACEi)/angiotensin II receptor blockers (ARBs) may increase the risk for a deleterious disease c...

Descripción completa

Detalles Bibliográficos
Autores principales: Dutsch, Alexander, Schunkert, Heribert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Medizin 2023
Materias:
Main Topic
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10127983/
https://www.ncbi.nlm.nih.gov/pubmed/37097476
http://dx.doi.org/10.1007/s00059-023-05168-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10127983/
https://www.ncbi.nlm.nih.gov/pubmed/37097476
http://dx.doi.org/10.1007/s00059-023-05168-4

Ejemplares similares